Biofrontera Inc. cash flow statement
In fiscal 2025, Biofrontera Inc.'s operations generated −$13.4m of cash; it spent $2,000 on capital projects, leaving free cash flow of −$13.4m.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | −12 | −27 | −16 | −25 | −10 | −13 | −8 |
| Depreciation and amortisation | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Stock-based pay | — | 0 | 2 | 1 | 1 | 1 | 1 |
| Capital spending | — | — | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | — | — | −16 | −25 | −10 | −13 | −8 |
| Free cash flow after stock pay | — | — | −18 | −26 | −11 | −14 | −9 |
| Shares issued | — | 15 | 9 | 5 | 8 | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −1,208 | −1,017 | −4,117 | −3,045 | −3,823 | −2,376 | −70 | −1,658 |
| Depreciation and amortisation | 20 | 359 | 29 | 0 | 9 | 74 | 55 | 0 |
| Stock-based pay | 288 | 299 | 239 | 187 | 236 | 289 | 342 | 263 |
| Capital spending | 0 | 1 | 3 | 1 | −1 | −1 | 5 | 0 |
| Free cash flow | −1,208 | −1,018 | −4,120 | −3,046 | −3,822 | −2,375 | −75 | −1,658 |
| Free cash flow after stock pay | −1,496 | −1,317 | −4,359 | −3,233 | −4,058 | −2,664 | −417 | −1,921 |
| Shares issued | 0 | 0 | — | — | — | — | — | — |
Compare with peers
- Cumberland Pharmaceuticals Inc cash flow
- Aquestive Therapeutics, Inc. cash flow
- IM Cannabis Corp. cash flow
- BGM Group Ltd. cash flow
- Aytu Biopharma, Inc cash flow
Head to head: BFRI vs CPIXAQST vs BFRIBFRI vs IMCC
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies